Company intelligence / Profile preview

Seal Rock Partners

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Developing second-generation ASK1 inhibitors for organ injury, inflammation, and fibrosis, with SRT-015 licensed to Genfit for ACLF (planned proof-of-concept in 2025). Optimized for improved safety profile over prior ASK1 inhibitors like selonsertib.

Therapeutic areas: NeurologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Genfit

Beyond the preview

Go deeper on Seal Rock Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seal Rock Partners.

Explore the full profile